AURA

Aura Biosciences, Inc. (AURA) - Q3 2024 10-Q Summary

Business Context and Reporting Period

Aura Biosciences, Inc. is a clinical-stage biotechnology company developing precision therapies for solid tumors, specifically focusing on ocular and urologic oncology. The company's lead product candidate, bel-sar (AU-011), is a Virus-Like Drug Conjugate (VDC) currently in a global Phase 3 CoMpass trial for early-stage choroidal melanoma. The company is also advancing bel-sar in Phase 1 trials for bladder cancer and metastases to the choroid. This report covers the quarterly period ended September 30, 2024.

Key Financial Metrics

Note: The company has no debt and an accumulated deficit of $348.4 million as of September 30, 2024.

Material Changes vs. Prior Period

• Increased Operating Loss: Net loss for the nine months ended September 30, 2024, increased by $6.8 million compared to the same period in 2023, driven primarily by higher personnel expenses and manufacturing development costs.
• R&D Spend: Research and development expenses increased by $6.0 million year-over-year for the nine-month period, attributed to the growth of the company and manufacturing development for bel-sar.
• Liquidity Position: Total cash, cash equivalents, and marketable securities decreased by approximately $66.3 million from the prior year-end ($240.7 million to $174.4 million) due to operating cash burn, partially offset by interest income of $7.4 million.
• Stock-Based Compensation: Stock-based compensation expense increased to $8.8 million for the nine months ended September 30, 2024, from $6.2 million in the prior year period.

Guidance, Outlook, and Risks

• Clinical Progress:
  • Choroidal Melanoma: Phase 2 end-of-study results presented in September 2024 showed an 80% tumor control rate and 90% visual acuity preservation in Phase 3-eligible patients. The Phase 3 CoMpass trial is ongoing with FDA Special Protocol Assessment (SPA) agreement.
  • Bladder Cancer: Positive early data from the Phase 1 trial announced in October 2024 showed clinical complete response in low-grade disease and visual tumor shrinkage in high-grade disease. A Phase 1b/2 expansion is planned for 2025.
• Liquidity Outlook: Management believes existing cash and marketable securities ($174.4 million) are sufficient to fund operations into the second half of 2026. No shares were issued under the At-The-Market (ATM) facility during the nine months ended September 30, 2024.
• Key Risks:
  • Capital Needs: The company has incurred significant losses since inception and expects to continue doing so. Future profitability depends entirely on the successful development and commercialization of bel-sar.
  • Regulatory Uncertainty: While an SPA was obtained for the Phase 3 trial, this does not guarantee approval. The novel nature of the VDC platform and the combination with a medical device (laser/microinjector) adds regulatory complexity.
  • Third-Party Reliance: The company relies on third-party CROs for clinical trials and CDMOs for manufacturing, creating risks related to supply chain, quality control, and timelines.

Investor Verification Checklist

• Cash Runway: Verify the accuracy of the "second half of 2026" funding estimate given the current burn rate of approximately $21 million per quarter.
• Phase 3 Enrollment: Monitor patient enrollment rates in the global Phase 3 CoMpass trial for choroidal melanoma to ensure timelines for data readout remain on track.
• Bladder Cancer Data: Review the full dataset from the Phase 1 bladder cancer trial to assess the durability of response and the design of the upcoming Phase 1b/2 expansion.
• Manufacturing Scale-up: Confirm the status of the transfer of manufacturing processes to commercial-scale CDMOs and any potential comparability studies required.
• ATM Facility Status: Monitor the status of the $350 million 2024 Shelf registration and the potential for future equity dilution if the company needs to raise capital sooner than anticipated.